Autopsy report · NCT02362451
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
Cause of deathSlow enrollment
“Slow accrual.”
Life of this trial
- Registered 5 months before it started.
- Ran for about 4 years 7 months before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 2 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Prostatic Neoplasms; Prostate Cancer
- Interventions
- Autologus elutriated monocyte placebo vaccine; Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
- Participants
- 7
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.